Baidu
map

Nature:造血细胞在骨髓内的动态调控

2017-03-31 Leo.C MedSci原创

骨髓内血细胞的形成,然后一步步分化为颗粒性细胞和巨噬细胞的原始细胞,再才逐步分化为颗粒性细胞和巨噬细胞,这一过程可以通过单细胞RNA测序技术来追踪和鉴别这一过程所产生的基因调整及变化。但是我们对于这一变化在骨髓中发生的空间结构的变化了解甚少。

对于造血功能的研究近年来,随着对于造血干细胞的研究以及技术的发展,有了新的突破。发现了多能干细胞(multipotent progenitor)在造血功能的重要性,鉴别了3种不同的多能干细胞,以及由他们特定分化而来的各种细胞,从而补充器官所需的各种细胞。具体来说,偏向分化髓系细胞的多能干细胞2、3亚型数量的上升,以及偏向分化淋巴细胞的多能干细胞4的调整,是骨髓内血细胞形成的关键第一步。

骨髓内血细胞的形成,然后一步步分化为颗粒性细胞和巨噬细胞的原始细胞,再才逐步分化为颗粒性细胞和巨噬细胞,这一过程可以通过单细胞RNA测序技术来追踪和鉴别这一过程所产生的基因调整及变化。但是我们对于这一变化在骨髓中发生的空间结构的变化了解甚少。

在最近一期的Nature杂志中,Aurélie Hérault及其同事报道了他们的发现。在未收到仍后激活信号的时候,颗粒性细胞和巨噬细胞的原始细胞在骨髓中是平均的分布以及自由的游弋的。但是在白血病病人和受到造血信号激活的情况下,这些个原始细胞会聚拢在一起。并且是原始细胞分化为颗粒性细胞和巨噬细胞这些功能性细胞的原始位点。并且当原始细胞聚拢到这一位点后,会发生一定的基因调控表现为激活一部分促进细胞周期的基因从而使细胞增殖。其中研究者发现在白血病病人和造血功能激活的骨髓细胞中有Irf8基因的下调。于是研究者在Irf8基因缺失的老鼠的骨髓中,发现在未收到造血信号的初始状态下就有造血原始细胞的聚集。而当细胞中β-catenin蛋白的量上升时,Irf8基因的表达量就下降。因此原始细胞在骨髓中的聚集是受到Irf8和β-catenin蛋白的双向调控的。

研究组进一步发现,从骨髓干细胞到多能原始细胞2、3亚型的分化,再到多能原始细胞在骨髓的聚集是受不同细胞因素的调控的。细胞激素SCF与IL1,在受到造血信号后首先分泌,促使骨髓干细胞转化到多能原始细胞2、3亚型。接着细胞激素G-CSF分泌,促进多能原始细胞下调Irf8,从而开始增殖。之后则开始分泌细胞激素TGFb1和CXCL4,抑制其增殖分化,使其恢复到平稳期。然而在白血病的情况下,激素TGFb1和CXCL4的分泌远远低于正常值,导致造血功能持续激活,从而最终导致白血病。未来可能,通过给予TGFb1和CXCL4在骨髓中抑制造血细胞的聚集从而治疗白血病。

原始初始:
Aurélie Hérault, Mikhail Binnewies, Stephanie Leong, et al. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature (2017) doi:10.1038/nature21693

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681817, encodeId=2fed168181eff, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Tue Oct 03 20:53:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881835, encodeId=dbc6188183506, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 14 04:53:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185180, encodeId=1564185180d6, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Apr 04 20:42:55 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184567, encodeId=14fb18456e61, content=不错的指南,为我们探讨研究提供了方针,给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Apr 02 12:59:13 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494540, encodeId=6e0b1494540d7, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621121, encodeId=65b0162112177, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681817, encodeId=2fed168181eff, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Tue Oct 03 20:53:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881835, encodeId=dbc6188183506, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 14 04:53:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185180, encodeId=1564185180d6, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Apr 04 20:42:55 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184567, encodeId=14fb18456e61, content=不错的指南,为我们探讨研究提供了方针,给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Apr 02 12:59:13 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494540, encodeId=6e0b1494540d7, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621121, encodeId=65b0162112177, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-11-14 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681817, encodeId=2fed168181eff, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Tue Oct 03 20:53:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881835, encodeId=dbc6188183506, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 14 04:53:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185180, encodeId=1564185180d6, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Apr 04 20:42:55 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184567, encodeId=14fb18456e61, content=不错的指南,为我们探讨研究提供了方针,给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Apr 02 12:59:13 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494540, encodeId=6e0b1494540d7, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621121, encodeId=65b0162112177, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-04-04 天涯183

    非常好的研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1681817, encodeId=2fed168181eff, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Tue Oct 03 20:53:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881835, encodeId=dbc6188183506, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 14 04:53:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185180, encodeId=1564185180d6, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Apr 04 20:42:55 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184567, encodeId=14fb18456e61, content=不错的指南,为我们探讨研究提供了方针,给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Apr 02 12:59:13 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494540, encodeId=6e0b1494540d7, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621121, encodeId=65b0162112177, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-04-02 ylzr123

    不错的指南,为我们探讨研究提供了方针,给点个赞了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1681817, encodeId=2fed168181eff, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Tue Oct 03 20:53:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881835, encodeId=dbc6188183506, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 14 04:53:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185180, encodeId=1564185180d6, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Apr 04 20:42:55 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184567, encodeId=14fb18456e61, content=不错的指南,为我们探讨研究提供了方针,给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Apr 02 12:59:13 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494540, encodeId=6e0b1494540d7, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621121, encodeId=65b0162112177, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-04-02 俅侠
  6. [GetPortalCommentsPageByObjectIdResponse(id=1681817, encodeId=2fed168181eff, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Tue Oct 03 20:53:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881835, encodeId=dbc6188183506, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 14 04:53:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185180, encodeId=1564185180d6, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Apr 04 20:42:55 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184567, encodeId=14fb18456e61, content=不错的指南,为我们探讨研究提供了方针,给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Apr 02 12:59:13 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494540, encodeId=6e0b1494540d7, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621121, encodeId=65b0162112177, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sun Apr 02 06:53:00 CST 2017, time=2017-04-02, status=1, ipAttribution=)]

相关资讯

Blood Cancer Journal:对付白血病的新办法,将“别吃我”变成“快吃我”

在急性髓系白血病(AML)中,异常红细胞通过表达“别吃我”的信号CD47,逃过免疫系统的攻击。如今,癌症研究人员通过新发现的CD47阻断抗体,将这个信号转化为“快吃我”,从而为白血病的治疗带来希望。

NEJM:浆细胞瘤和浆细胞白血病 -案例报道

浆细胞性白血病是一种罕见且高度侵袭性的浆细胞疾病,可表现为原发性疾病或多发性骨髓瘤的进展或复发。

BMJ:淤斑和异常白细胞-案例报道

病人采用全反式维甲酸和伊达比星治疗,并已获得全面恢复。该患者完全康复,目前正在积极监测病情,每三个月进行骨髓PML-RARA PCR转录检查。

Leukemia:意大利科学家筛选出精准治疗白血病的潜在新药

近日,来自意大利的科学家在自然旗下期刊Leukemia上发表了一项最新研究进展,他们发现一种组蛋白去乙酰化酶抑制剂能够选择性杀伤发生某个基因重排的B前体细胞急性淋巴细胞白血病(BCP-ALL),该研究为这种难治白血病亚型的治疗提供了新的潜在药物。携带CRLF2和JAK2基因变异的白血病细胞存在JAK/STAT信号途径的异常,并且病人往往预后

Nat Med:靶向两分子或有助于彻底治愈白血病

科学家在癌细胞内发现两个信号蛋白能够让癌细胞抵抗化疗,研究表明阻断这两种蛋白能够增强化疗对人类白血病小鼠模型的治疗效果。相关研究结果发表在国际学术期刊Nature Medicine上。

美国FDA批准施维雅/辉瑞通用型CAR-T疗法进入临床试验

  2017年3月13日讯 /生物谷BIOON/ --美国制药巨头辉瑞(Pfizer)与法国药企施维雅(Servier)及法国生物技术公司Cellectis近日联合宣布,CAR-T细胞疗法UCART19的实验性新药申请(IND)已获得了美国食品和药物管理局(FDA)的批准,可以在美国开展人体临床试验,用于复发性/难治性急性淋巴细胞白血病(ALL)的治疗。 施维雅将负责UCAR

Baidu
map
Baidu
map
Baidu
map